UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

 

 

FORM SD

Specialized Disclosure Report

 

 

 

CYTORI THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

DELAWARE

001-34375

33-0827593

(State or other jurisdiction of incorporation or organization)

(Commission File Number)

(IRS Employer Identification No.)

 

 

 

 

 

 

 

 

 

3020 Callan Road,

 

 

San Diego, California

 

92121

(Address of principal executive officers)

 

(Zip Code)

Gary Titus

Chief Financial Officer

(858) 458-0900

 

(Name and Telephone number, including area code, of the person to contact in connection with this report.)

 

 

 

Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:

 

[ ]  Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2018.


1

 


 

SECTION 1 – Conflict Minerals Disclosure

 

Item 1.01 - Conflict Minerals Report

 

Cytori Therapeutics, Inc. has included the Conflict Minerals Report as an exhibit to its Form SD for the period from January 1, 2018 to December 31, 2018. Unless the context otherwise indicates, “Cytori,” “the Company,” “we,” “us” and “our” refer to Cytori Therapeutics, Inc. and its consolidated subsidiaries.

 

For the year 2018, certain of our operations manufactured, or contracted to manufacture, products for which 3TGs, as defined below, are necessary to their functionality or production (“Covered Products”). Conflict minerals are defined in Section 13(p) as (A) cassiterite, columbite-tantalite (coltan), gold, wolframite, and their derivatives, which are limited to tin, tantalum and tungsten (together with gold collectively referred to as 3TGs), or (B) any other mineral or its derivatives determined by the Secretary of State to be financing conflict in the Democratic Republic of Congo ("DRC") or any adjoining country that shares an internationally recognized border with the DRC (the “Covered Countries”). Accordingly, we have conducted a reasonable country of origin inquiry (“RCOI”) that was designed to determine whether any of the 3TGs in our Covered Products originated in the Democratic Republic of the Congo or an adjoining country (Angola, Burundi, the Central African Republic, the Republic of the Congo, Rwanda, South Sudan, Tanzania, Uganda or Zambia), or were from recycled or scrap sources.

 

A summary of our RCOI and steps of due diligence on the source and chain of custody of any 3TGs in our Covered Products, is included in our Conflict Minerals Report, which is filed as Exhibit 1.01 to this Form SD.  In addition to this, our Conflict Minerals Report is publicly available on our company website at: www.cytori.com.

 

 

Forward-Looking Statements

The Report contains forward -looking statements which express a belief, expectation or intention, as well as those that are historical fact, are forward-looking statements, including statements relating to our compliance efforts and expected actions.  The words “expects,” “intends,” “plans,” “believes,” and “anticipates” and similar expressions are used to identify these forward-looking statements. These statements are not guarantees of future actions or performance and are subject to various risks, uncertainties and assumptions. Undue reliance should not be placed on these statements, which are only effective as of the date of this report, and the Company undertakes no obligation to publicly update or revise any forward-looking statement.

 

Item 1.02 Exhibit.

 

We have filed our Conflict Minerals Report as Exhibit 1.01 to this Form SD.

 

Item 2.01 Exhibits.

 

Exhibit 1.01 – Conflict Minerals Report as required by Item 1.01. of Form SD.

 

 

 

EXHIBIT INDEX

 

 


2

 


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

 

 

 

CYTORI THERAPEUTICS, INC.

 

 

 

May 30, 2019

By:

/s/ Gary Titus

Gary Titus

Chief Financial Officer

 

 

 

 

 

3

 

Cytori Therapeutics (NASDAQ:CYTX)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Cytori Therapeutics Charts.
Cytori Therapeutics (NASDAQ:CYTX)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Cytori Therapeutics Charts.